Speakers: Jonathan M. Barasch (Columbia University Medical Center), Colin Meyer (Reata Pharmaceuticals, Inc.), ND Vaziri (University of California, Irvine), and David Warnock (University of Alabama at Birmingham)
Organizers: Colin Meyer (Reata Pharmaceuticals, Inc.), George Zavoico (MLV), and Jennifer Henry (The New York Academy of Sciences)Presented by Hot Topics in Life Sciences
Reported by Jennifer Cable | Posted April 16, 2012
Chronic kidney disease (CKD) is a progressive loss of kidney function that generally results from type 2 diabetes and hypertension. While current treatments can maintain kidney function and slow the progression of disease, there is nothing available that improves kidney function. In December 2011, researchers from academia and industry met at the New York Academy of Sciences for the symposium Chronic Kidney Disease: Inflammation and Oxidative Stress in Pathogenesis and Clinical Course to discuss an emerging approach toward CKD—targeting inflammation. The seminar was presented by the Academy, Fistula First, the Journal of Clinical Investigation, and Genzyme. The speakers presented an overview of the role of oxidative stress and inflammation in CKD, highlighting the current unmet needs in the diagnosis and treatment of CKD and presenting promising results for a new diagnostic marker of CKD as well as a new drug that improves kidney function by inhibiting pro-inflammatory pathways.
Use the tabs above to find a meeting report and multimedia from this event.
Presentations available from:
Jonathan Barasch, MD, PhD (Columbia University Medical Center)
Colin Meyer, MD (Reata Pharmaceuticals, Inc.)
ND Vaziri, MD (University of California, Irvine)
David Warnock, MD (University of Alabama at Birmingham)
George Zavoico, PhD (MLV)
Genzyme CorporationLog in or Join Now to continue